Back to search

Article

Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)

2026-02-17

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Platinum-based chemotherapy followed by second-line immunotherapy has been traditionally the standard of care for locally advanced or metastatic urothelial cancer (La/mUC). However, checkpoint inhibitors are remarkably reshaping the therapeutic landscape for urothelial cancer. Despite these advances, La/mUC remains a highly lethal disease with poor prognosis a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9c7e32c8-6387-532c-bedf-e9e35698ad7b
DOI
10.21203/rs.3.rs-8651439/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)DOI 10.21203/rs.3.rs-8651439/v1
Histological variant-specific significance of lymph node metastasis for the prognosis of metastatic urothelial carcinoma treated with pembrolizumab: A retrospective multicentric study (YUSHIMA study-04)Semantic proximity
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.Semantic proximity
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaSemantic proximity
BioBladder – a national longitudinal sampling study providing a comprehensive framework to precision oncology in urothelial cancerSemantic proximity
Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective studySemantic proximity
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.Semantic proximity
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trialSemantic proximity
Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current DevelopmentSemantic proximity
Urinary Biomarkers in Urothelial Carcinoma: Expanded Con-temporary Evidence for Diagnosis, Surveillance, Risk Stratification, and Cystoscopy-Sparing Clinical PathwaysSemantic proximity
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experienceSemantic proximity
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Semantic proximity
Current State of Art Therapy for MPM and Future Options Focus on ImmunotherapySemantic proximity
Select a neighboring publication to make it the new centre.